Auro Laboratories [AUROLAB] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Auro Laboratories
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Auro Laboratories wins in 2 metrics, Aarti Drugs wins in 15 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Auro Laboratories | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 85.07 | 23.75 | Aarti Drugs |
| Price-to-Book Ratio | 3.65 | 3.28 | Aarti Drugs |
| Debt-to-Equity Ratio | 104.76 | 44.92 | Aarti Drugs |
| PEG Ratio | N/A | 0.37 | N/A |
| EV/EBITDA | 98.60 | 17.15 | Aarti Drugs |
| Profit Margin (TTM) | 5.96% | 7.80% | Aarti Drugs |
| Operating Margin (TTM) | -8.69% | 10.11% | Aarti Drugs |
| EBITDA Margin (TTM) | N/A | 10.11% | N/A |
| Return on Equity | 4.28% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 1.86% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $-180.54M | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | 27.16% | -16.47% | Auro Laboratories |
| Price-to-Sales Ratio (TTM) | 9.51 | 1.85 | Aarti Drugs |
| Enterprise Value | $2.08B | $50.72B | Aarti Drugs |
| EV/Revenue Ratio | 12.65 | 2.09 | Aarti Drugs |
| Gross Profit Margin (TTM) | 31.59% | 36.77% | Aarti Drugs |
| Revenue per Share (TTM) | $26 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $2.95 | $20.66 | Aarti Drugs |
| Beta (Stock Volatility) | 0.20 | 0.21 | Auro Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Auro Laboratories vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Auro Laboratories | -3.32% | -2.98% | -9.91% | 0.49% | 10.14% | -2.74% |
| Aarti Drugs | 2.56% | -3.22% | -13.59% | -0.59% | 21.36% | 3.40% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Auro Laboratories | 27.16% | 230.13% | 351.23% | 1,605.67% | 5,058.27% | 3,066.46% |
| Aarti Drugs | -16.47% | 7.52% | -35.72% | 228.84% | 2,611.57% | 2,363.39% |
Performance & Financial Health Analysis: Auro Laboratories vs Aarti Drugs
| Metric | AUROLAB | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.56B | ₹44.80B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 4,233 | 150,557 |
| 90 Day Avg. Volume | 6,076 | 593,779 |
| Last Close | ₹247.35 | ₹483.05 |
| 52 Week Range | ₹170.00 - ₹303.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -18.37% | -23.93% |
| All-Time High | ₹307.20 (May 06, 2024) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -19.48% | -52.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.52% | 0.06% |
| Quarterly Earnings Growth | -0.32% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.08% |
| Operating Margin (TTM) | -0.09% | 0.10% |
| Return on Equity (TTM) | 0.04% | 0.12% |
| Debt to Equity (MRQ) | 104.76 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹68.67 | ₹149.84 |
| Cash per Share (MRQ) | ₹1.02 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹74.16M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹18.39M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Auro Laboratories vs Aarti Drugs
| Metric | AUROLAB | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 85.07 | 23.75 |
| Forward P/E | N/A | 14.98 |
| PEG Ratio | N/A | 0.37 |
| Price to Sales (TTM) | 9.51 | 1.85 |
| Price to Book (MRQ) | 3.65 | 3.28 |
| Market Capitalization | ||
| Market Capitalization | ₹1.56B | ₹44.80B |
| Enterprise Value | ₹2.08B | ₹50.72B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 12.65 | 2.09 |
| Enterprise to EBITDA | 98.60 | 17.15 |
| Risk & Other Metrics | ||
| Beta | 0.20 | 0.21 |
| Book Value per Share (MRQ) | ₹68.67 | ₹149.84 |
Financial Statements Comparison: Auro Laboratories vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AUROLAB | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹75.40M | ₹6.77B |
| Cost of Goods Sold | ₹51.58M | ₹4.37B |
| Gross Profit | ₹23.82M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹6.47M | ₹784.50M |
| EBITDA | ₹9.19M | ₹951.90M |
| Pre-Tax Income | ₹3.29M | ₹711.50M |
| Income Tax | ₹-3.49M | ₹83.80M |
| Net Income (Profit) | ₹6.77M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AUROLAB | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹3,000 | ₹45.80M |
| Total Current Assets | ₹215.14M | ₹13.38B |
| Total Current Liabilities | ₹216.42M | ₹8.37B |
| Long-Term Debt | ₹330.85M | ₹2.86B |
| Total Shareholders Equity | ₹429.68M | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹210.58M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AUROLAB | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AUROLAB | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 4,233 | 150,557 |
| Average Daily Volume (90 Day) | 6,076 | 593,779 |
| Shares Outstanding | 6.23M | 91.27M |
| Float Shares | 2.50M | 35.46M |
| % Held by Insiders | 0.60% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Auro Laboratories vs Aarti Drugs
| Metric | AUROLAB | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | N/A | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | N/A | ₹3.00 |
| Ex-Dividend Date | N/A | Feb 04, 2025 |